Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease
Identifieur interne : 004624 ( Main/Merge ); précédent : 004623; suivant : 004625Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease
Auteurs : Thanh G. Ton [États-Unis] ; Susan R. Heckbert [États-Unis] ; W. T. Longstreth Jr. [États-Unis] ; Mary Anne Rossing [États-Unis] ; Walter A. Kukull [États-Unis] ; Gary M. Franklin [États-Unis] ; Phillip D. Swanson [États-Unis] ; Terri Smith-Weller [États-Unis] ; Harvey Checkoway [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-07.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal (administration & dosage), Aspirin (administration & dosage), Case-Control Studies, Cross-Sectional Studies, Female, Humans, Ibuprofen (administration & dosage), Male, Middle Aged, NSAIDs, Odds Ratio, Oxidative Stress (drug effects), Parkinson Disease (diagnosis), Parkinson Disease (epidemiology), Parkinson Disease (prevention & control), Parkinson's disease, Retrospective Studies, Risk, Washington, aspirin, inflammation, nonsteroidal anti‐inflammatory drugs.
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Ibuprofen.
- geographic : Washington.
- diagnosis : Parkinson Disease.
- drug effects : Oxidative Stress.
- epidemiology : Parkinson Disease.
- prevention & control : Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Odds Ratio, Retrospective Studies, Risk.
Abstract
Inflammation and oxidative stress have been implicated as pathogenic mechanisms in Parkinson's disease (PD). Evidence from in vitro and animal studies suggests a possible protective role of nonsteroidal anti‐inflammatory drugs (NSAIDs), including aspirin. We investigated the risk of PD associated with use of aspirin and nonaspirin NSAIDs in a population‐based case‐control study among enrollees of Group Health Cooperative, a health maintenance organization in the Seattle area. Subjects included 206 cases between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 randomly selected controls frequency‐matched by age, sex, duration of enrollment, and clinic. We obtained information on participants' age, smoking, and medical history from interview. Exposure to NSAIDs was ascertained from an automated pharmacy database. Medications filled within 5 years of the interview were excluded. After adjusting for age, sex, smoking, duration of enrollment, and clinic, the risk of PD among individuals who received nonaspirin NSAIDs between 1977 and 1992 was 0.90 (95% CI: 0.59–1.35) and 1.67 (95% CI: 0.60–4.60) between 1993 and 2002. Use of ibuprofen was not associated with PD (OR: 0.89; 95% CI: 0.60–1.32). The risk of PD associated with aspirin or aspirin‐containing medications was 0.74 (95% CI: 0.49–1.12). We observed no trend in risk according to number of fills for these drugs. Our results provide only limited support for the hypothesis that use of aspirin may reduce the risk of this disease, and no indication of protection from other NSAIDs. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20856
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001411
- to stream Istex, to step Curation: 001411
- to stream Istex, to step Checkpoint: 001D70
- to stream PubMed, to step Corpus: 002D17
- to stream PubMed, to step Curation: 002D17
- to stream PubMed, to step Checkpoint: 002C03
- to stream Ncbi, to step Merge: 001614
- to stream Ncbi, to step Curation: 001614
- to stream Ncbi, to step Checkpoint: 001614
Links to Exploration step
ISTEX:D8CE3A218198D995E290A58653036C4A21D91D69Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease</title><author><name sortKey="Ton, Thanh G" sort="Ton, Thanh G" uniqKey="Ton T" first="Thanh G." last="Ton">Thanh G. Ton</name></author><author><name sortKey="Heckbert, Susan R" sort="Heckbert, Susan R" uniqKey="Heckbert S" first="Susan R." last="Heckbert">Susan R. Heckbert</name></author><author><name sortKey="Longstreth Jr, W T" sort="Longstreth Jr, W T" uniqKey="Longstreth Jr W" first="W. T." last="Longstreth Jr.">W. T. Longstreth Jr.</name></author><author><name sortKey="Rossing, Mary Anne" sort="Rossing, Mary Anne" uniqKey="Rossing M" first="Mary Anne" last="Rossing">Mary Anne Rossing</name></author><author><name sortKey="Kukull, Walter A" sort="Kukull, Walter A" uniqKey="Kukull W" first="Walter A." last="Kukull">Walter A. Kukull</name></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M." last="Franklin">Gary M. Franklin</name></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D." last="Swanson">Phillip D. Swanson</name></author><author><name sortKey="Smith Eller, Terri" sort="Smith Eller, Terri" uniqKey="Smith Eller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D8CE3A218198D995E290A58653036C4A21D91D69</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20856</idno><idno type="url">https://api.istex.fr/document/D8CE3A218198D995E290A58653036C4A21D91D69/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001411</idno><idno type="wicri:Area/Istex/Curation">001411</idno><idno type="wicri:Area/Istex/Checkpoint">001D70</idno><idno type="wicri:doubleKey">0885-3185:2006:Ton T:nonsteroidal:anti:inflammatory</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16550541</idno><idno type="wicri:Area/PubMed/Corpus">002D17</idno><idno type="wicri:Area/PubMed/Curation">002D17</idno><idno type="wicri:Area/PubMed/Checkpoint">002C03</idno><idno type="wicri:Area/Ncbi/Merge">001614</idno><idno type="wicri:Area/Ncbi/Curation">001614</idno><idno type="wicri:Area/Ncbi/Checkpoint">001614</idno><idno type="wicri:doubleKey">0885-3185:2006:Ton T:nonsteroidal:anti:inflammatory</idno><idno type="wicri:Area/Main/Merge">004624</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease</title><author><name sortKey="Ton, Thanh G" sort="Ton, Thanh G" uniqKey="Ton T" first="Thanh G." last="Ton">Thanh G. Ton</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Heckbert, Susan R" sort="Heckbert, Susan R" uniqKey="Heckbert S" first="Susan R." last="Heckbert">Susan R. Heckbert</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Longstreth Jr, W T" sort="Longstreth Jr, W T" uniqKey="Longstreth Jr W" first="W. T." last="Longstreth Jr.">W. T. Longstreth Jr.</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Rossing, Mary Anne" sort="Rossing, Mary Anne" uniqKey="Rossing M" first="Mary Anne" last="Rossing">Mary Anne Rossing</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Kukull, Walter A" sort="Kukull, Walter A" uniqKey="Kukull W" first="Walter A." last="Kukull">Walter A. Kukull</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M." last="Franklin">Gary M. Franklin</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, Seattle, University of Washington, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D." last="Swanson">Phillip D. Swanson</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Smith Eller, Terri" sort="Smith Eller, Terri" uniqKey="Smith Eller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, Seattle, University of Washington, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, Seattle, University of Washington, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-07">2006-07</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="964">964</biblScope><biblScope unit="page" to="969">969</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D8CE3A218198D995E290A58653036C4A21D91D69</idno><idno type="DOI">10.1002/mds.20856</idno><idno type="ArticleID">MDS20856</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)</term><term>Aspirin (administration & dosage)</term><term>Case-Control Studies</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Ibuprofen (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>NSAIDs</term><term>Odds Ratio</term><term>Oxidative Stress (drug effects)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (prevention & control)</term><term>Parkinson's disease</term><term>Retrospective Studies</term><term>Risk</term><term>Washington</term><term>aspirin</term><term>inflammation</term><term>nonsteroidal anti‐inflammatory drugs</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Aspirin</term><term>Ibuprofen</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Washington</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Oxidative Stress</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Retrospective Studies</term><term>Risk</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Inflammation and oxidative stress have been implicated as pathogenic mechanisms in Parkinson's disease (PD). Evidence from in vitro and animal studies suggests a possible protective role of nonsteroidal anti‐inflammatory drugs (NSAIDs), including aspirin. We investigated the risk of PD associated with use of aspirin and nonaspirin NSAIDs in a population‐based case‐control study among enrollees of Group Health Cooperative, a health maintenance organization in the Seattle area. Subjects included 206 cases between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 randomly selected controls frequency‐matched by age, sex, duration of enrollment, and clinic. We obtained information on participants' age, smoking, and medical history from interview. Exposure to NSAIDs was ascertained from an automated pharmacy database. Medications filled within 5 years of the interview were excluded. After adjusting for age, sex, smoking, duration of enrollment, and clinic, the risk of PD among individuals who received nonaspirin NSAIDs between 1977 and 1992 was 0.90 (95% CI: 0.59–1.35) and 1.67 (95% CI: 0.60–4.60) between 1993 and 2002. Use of ibuprofen was not associated with PD (OR: 0.89; 95% CI: 0.60–1.32). The risk of PD associated with aspirin or aspirin‐containing medications was 0.74 (95% CI: 0.49–1.12). We observed no trend in risk according to number of fills for these drugs. Our results provide only limited support for the hypothesis that use of aspirin may reduce the risk of this disease, and no indication of protection from other NSAIDs. © 2006 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.20856"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease</title><author><name sortKey="Ton, Thanh G" sort="Ton, Thanh G" uniqKey="Ton T" first="Thanh G." last="Ton">Thanh G. Ton</name></author><author><name sortKey="Heckbert, Susan R" sort="Heckbert, Susan R" uniqKey="Heckbert S" first="Susan R." last="Heckbert">Susan R. Heckbert</name></author><author><name sortKey="Longstreth Jr, W T" sort="Longstreth Jr, W T" uniqKey="Longstreth Jr W" first="W. T." last="Longstreth Jr.">W. T. Longstreth Jr.</name></author><author><name sortKey="Rossing, Mary Anne" sort="Rossing, Mary Anne" uniqKey="Rossing M" first="Mary Anne" last="Rossing">Mary Anne Rossing</name></author><author><name sortKey="Kukull, Walter A" sort="Kukull, Walter A" uniqKey="Kukull W" first="Walter A." last="Kukull">Walter A. Kukull</name></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M." last="Franklin">Gary M. Franklin</name></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D." last="Swanson">Phillip D. Swanson</name></author><author><name sortKey="Smith Eller, Terri" sort="Smith Eller, Terri" uniqKey="Smith Eller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D8CE3A218198D995E290A58653036C4A21D91D69</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20856</idno><idno type="url">https://api.istex.fr/document/D8CE3A218198D995E290A58653036C4A21D91D69/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001411</idno><idno type="wicri:Area/Istex/Curation">001411</idno><idno type="wicri:Area/Istex/Checkpoint">001D70</idno><idno type="wicri:doubleKey">0885-3185:2006:Ton T:nonsteroidal:anti:inflammatory</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease</title><author><name sortKey="Ton, Thanh G" sort="Ton, Thanh G" uniqKey="Ton T" first="Thanh G." last="Ton">Thanh G. Ton</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Heckbert, Susan R" sort="Heckbert, Susan R" uniqKey="Heckbert S" first="Susan R." last="Heckbert">Susan R. Heckbert</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Longstreth Jr, W T" sort="Longstreth Jr, W T" uniqKey="Longstreth Jr W" first="W. T." last="Longstreth Jr.">W. T. Longstreth Jr.</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Rossing, Mary Anne" sort="Rossing, Mary Anne" uniqKey="Rossing M" first="Mary Anne" last="Rossing">Mary Anne Rossing</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Kukull, Walter A" sort="Kukull, Walter A" uniqKey="Kukull W" first="Walter A." last="Kukull">Walter A. Kukull</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M." last="Franklin">Gary M. Franklin</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, Seattle, University of Washington, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D." last="Swanson">Phillip D. Swanson</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Smith Eller, Terri" sort="Smith Eller, Terri" uniqKey="Smith Eller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, Seattle, University of Washington, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, Seattle, University of Washington, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-07">2006-07</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="964">964</biblScope><biblScope unit="page" to="969">969</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D8CE3A218198D995E290A58653036C4A21D91D69</idno><idno type="DOI">10.1002/mds.20856</idno><idno type="ArticleID">MDS20856</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>NSAIDs</term><term>Parkinson's disease</term><term>aspirin</term><term>inflammation</term><term>nonsteroidal anti‐inflammatory drugs</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Inflammation and oxidative stress have been implicated as pathogenic mechanisms in Parkinson's disease (PD). Evidence from in vitro and animal studies suggests a possible protective role of nonsteroidal anti‐inflammatory drugs (NSAIDs), including aspirin. We investigated the risk of PD associated with use of aspirin and nonaspirin NSAIDs in a population‐based case‐control study among enrollees of Group Health Cooperative, a health maintenance organization in the Seattle area. Subjects included 206 cases between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 randomly selected controls frequency‐matched by age, sex, duration of enrollment, and clinic. We obtained information on participants' age, smoking, and medical history from interview. Exposure to NSAIDs was ascertained from an automated pharmacy database. Medications filled within 5 years of the interview were excluded. After adjusting for age, sex, smoking, duration of enrollment, and clinic, the risk of PD among individuals who received nonaspirin NSAIDs between 1977 and 1992 was 0.90 (95% CI: 0.59–1.35) and 1.67 (95% CI: 0.60–4.60) between 1993 and 2002. Use of ibuprofen was not associated with PD (OR: 0.89; 95% CI: 0.60–1.32). The risk of PD associated with aspirin or aspirin‐containing medications was 0.74 (95% CI: 0.49–1.12). We observed no trend in risk according to number of fills for these drugs. Our results provide only limited support for the hypothesis that use of aspirin may reduce the risk of this disease, and no indication of protection from other NSAIDs. © 2006 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease.</title><author><name sortKey="Ton, Thanh G" sort="Ton, Thanh G" uniqKey="Ton T" first="Thanh G" last="Ton">Thanh G. Ton</name><affiliation wicri:level="4"><nlm:affiliation>Department of Epidemiology, University of Washington, Seattle, Washington 98195, USA. thanhton@u.washington.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington 98195</wicri:regionArea><orgName type="university">Université de Washington</orgName><placeName><settlement type="city">Seattle</settlement><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Heckbert, Susan R" sort="Heckbert, Susan R" uniqKey="Heckbert S" first="Susan R" last="Heckbert">Susan R. Heckbert</name></author><author><name sortKey="Longstreth, W T" sort="Longstreth, W T" uniqKey="Longstreth W" first="W T" last="Longstreth">W T Longstreth</name></author><author><name sortKey="Rossing, Mary Anne" sort="Rossing, Mary Anne" uniqKey="Rossing M" first="Mary Anne" last="Rossing">Mary Anne Rossing</name></author><author><name sortKey="Kukull, Walter A" sort="Kukull, Walter A" uniqKey="Kukull W" first="Walter A" last="Kukull">Walter A. Kukull</name></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M" last="Franklin">Gary M. Franklin</name></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D" last="Swanson">Phillip D. Swanson</name></author><author><name sortKey="Smith Weller, Terri" sort="Smith Weller, Terri" uniqKey="Smith Weller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20856</idno><idno type="RBID">pubmed:16550541</idno><idno type="pmid">16550541</idno><idno type="wicri:Area/PubMed/Corpus">002D17</idno><idno type="wicri:Area/PubMed/Curation">002D17</idno><idno type="wicri:Area/PubMed/Checkpoint">002C03</idno><idno type="wicri:Area/Ncbi/Merge">001614</idno><idno type="wicri:Area/Ncbi/Curation">001614</idno><idno type="wicri:Area/Ncbi/Checkpoint">001614</idno><idno type="wicri:doubleKey">0885-3185:2006:Ton T:nonsteroidal:anti:inflammatory</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease.</title><author><name sortKey="Ton, Thanh G" sort="Ton, Thanh G" uniqKey="Ton T" first="Thanh G" last="Ton">Thanh G. Ton</name><affiliation wicri:level="4"><nlm:affiliation>Department of Epidemiology, University of Washington, Seattle, Washington 98195, USA. thanhton@u.washington.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington 98195</wicri:regionArea><orgName type="university">Université de Washington</orgName><placeName><settlement type="city">Seattle</settlement><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Heckbert, Susan R" sort="Heckbert, Susan R" uniqKey="Heckbert S" first="Susan R" last="Heckbert">Susan R. Heckbert</name></author><author><name sortKey="Longstreth, W T" sort="Longstreth, W T" uniqKey="Longstreth W" first="W T" last="Longstreth">W T Longstreth</name></author><author><name sortKey="Rossing, Mary Anne" sort="Rossing, Mary Anne" uniqKey="Rossing M" first="Mary Anne" last="Rossing">Mary Anne Rossing</name></author><author><name sortKey="Kukull, Walter A" sort="Kukull, Walter A" uniqKey="Kukull W" first="Walter A" last="Kukull">Walter A. Kukull</name></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M" last="Franklin">Gary M. Franklin</name></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D" last="Swanson">Phillip D. Swanson</name></author><author><name sortKey="Smith Weller, Terri" sort="Smith Weller, Terri" uniqKey="Smith Weller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)</term><term>Aspirin (administration & dosage)</term><term>Case-Control Studies</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Ibuprofen (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Oxidative Stress (drug effects)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (prevention & control)</term><term>Retrospective Studies</term><term>Risk</term><term>Washington</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Aspirin</term><term>Ibuprofen</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Washington</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Oxidative Stress</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Retrospective Studies</term><term>Risk</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Inflammation and oxidative stress have been implicated as pathogenic mechanisms in Parkinson's disease (PD). Evidence from in vitro and animal studies suggests a possible protective role of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin. We investigated the risk of PD associated with use of aspirin and nonaspirin NSAIDs in a population-based case-control study among enrollees of Group Health Cooperative, a health maintenance organization in the Seattle area. Subjects included 206 cases between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 randomly selected controls frequency-matched by age, sex, duration of enrollment, and clinic. We obtained information on participants' age, smoking, and medical history from interview. Exposure to NSAIDs was ascertained from an automated pharmacy database. Medications filled within 5 years of the interview were excluded. After adjusting for age, sex, smoking, duration of enrollment, and clinic, the risk of PD among individuals who received nonaspirin NSAIDs between 1977 and 1992 was 0.90 (95% CI: 0.59-1.35) and 1.67 (95% CI: 0.60-4.60) between 1993 and 2002. Use of ibuprofen was not associated with PD (OR: 0.89; 95% CI: 0.60-1.32). The risk of PD associated with aspirin or aspirin-containing medications was 0.74 (95% CI: 0.49-1.12). We observed no trend in risk according to number of fills for these drugs. Our results provide only limited support for the hypothesis that use of aspirin may reduce the risk of this disease, and no indication of protection from other NSAIDs.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004624 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004624 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:D8CE3A218198D995E290A58653036C4A21D91D69
|texte= Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |